CA2336382A1 - Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens - Google Patents

Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens Download PDF

Info

Publication number
CA2336382A1
CA2336382A1 CA002336382A CA2336382A CA2336382A1 CA 2336382 A1 CA2336382 A1 CA 2336382A1 CA 002336382 A CA002336382 A CA 002336382A CA 2336382 A CA2336382 A CA 2336382A CA 2336382 A1 CA2336382 A1 CA 2336382A1
Authority
CA
Canada
Prior art keywords
antigen
immune
cells
privileged
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002336382A
Other languages
English (en)
French (fr)
Inventor
Robert B. Darnell
Matthew L. Albert
Nina Bhardwaj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2336382A1 publication Critical patent/CA2336382A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
CA002336382A 1998-06-30 1999-06-30 Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens Abandoned CA2336382A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10797898A 1998-06-30 1998-06-30
US09/107,978 1998-06-30
PCT/US1999/014827 WO2000000825A2 (en) 1998-06-30 1999-06-30 Detection and modulation of cellular immunity to immune privileged antigens
USUNKNOWN 2003-11-13

Publications (1)

Publication Number Publication Date
CA2336382A1 true CA2336382A1 (en) 2000-01-06

Family

ID=22319532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002336382A Abandoned CA2336382A1 (en) 1998-06-30 1999-06-30 Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens

Country Status (4)

Country Link
JP (1) JP2004510950A (ja)
AU (1) AU4848899A (ja)
CA (1) CA2336382A1 (ja)
WO (1) WO2000000825A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1092154A2 (en) 1998-06-30 2001-04-18 The Rockefeller University Detection and modulation of cellular immunity to immune privileged antigens
BR0010322A (pt) * 1999-05-06 2002-04-09 Univ Wake Forest Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero
WO2001057534A2 (en) * 2000-02-04 2001-08-09 Bioseek Compositions and methods for reducing autoimmunity
WO2002036748A2 (en) * 2000-11-03 2002-05-10 Nexell Therapeutics, Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
EP1734663B1 (en) 2005-06-17 2011-06-15 Fujitsu Limited Multi-hop communication system
US7928190B2 (en) * 2007-07-05 2011-04-19 Darnell Robert B Methods and compositions for tumor vaccination and therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019635A1 (en) * 1991-04-25 1992-11-12 Sloan-Kettering Institute For Cancer Research Antigen recognized by antibodies associated with paraneoplastic opsoclonus and methods of use thereof
AU2484892A (en) * 1991-08-09 1993-03-02 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
US5753522A (en) * 1991-12-06 1998-05-19 Legacy Good Samaritan Hospital And Medical Center Purified protein for identifying a cancer-associated retinopathy autoantibody
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
WO2000000825A2 (en) 2000-01-06
WO2000000825A3 (en) 2000-02-10
WO2000000825A9 (en) 2000-05-25
JP2004510950A (ja) 2004-04-08
AU4848899A (en) 2000-01-17

Similar Documents

Publication Publication Date Title
Allenbach et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis
Jagessar et al. Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete freund adjuvant
AU2008290061B2 (en) CDCA1 peptide and pharmaceutical agent comprising the same
Xu et al. Genetic deficiency of Irgm1 (LRG-47) suppresses induction of experimental autoimmune encephalomyelitis by promoting apoptosis of activated CD4+ T cells
Johnson et al. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?
Honma et al. Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism
Perera et al. Active immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injury
JP2006512396A (ja) 免疫寛容を誘導および維持する方法
IL195115A (en) Personalized t-cell vaccine for the treatment of multiple sclerosis and methods of making same
KR20210041559A (ko) 다발경화증에서의 면역우세 단백질 및 단편
US11567078B2 (en) Blood cell biomarker for late onset Alzheimer's disease
US20130004528A1 (en) Direct analysis of antigen-specific immune response
CA2336382A1 (en) Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens
US6750029B1 (en) Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens
JPWO2009034961A1 (ja) ヒト樹状細胞の評価方法およびヒト細胞免疫療法剤
Cao et al. CTRP4 binds to the interleukin-6 Receptor and ameliorates autoimmune encephalomyelitis by suppressing Th17 cell differentiation
Gupta Inhibiting Auto-Antigen Presentation on MHC Class-II by Small Molecules in Sjogren’s Syndrome
Griesenauer et al. ST2/MyD88 deficiency protects mice against aGVHD and spares T-regulatory cells
Kuo Association of local immune suppression in skin with HPV-induced epithelial hyperplasia
Roed et al. Myelin specific T-cells CD4
Wagner How myelin-specific CD8 T cells contribute to CNS autoimmunity.
Shono et al. A small molecule c-Rel inhibitor reduces alloactivation of T-cells
US20150362508A1 (en) Effector t cell rsistance
Fairhead The Role of RIP2 in Vascularized Allograft Rejection

Legal Events

Date Code Title Description
FZDE Dead